2008-05-14 01:55:00 -

www.combinatorx.com - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that Alexis Borisy, President and CEO is scheduled to present at the upcoming Rodman & Renshaw Annual Global Healthcare Conference at the Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco. Mr. Borisy is scheduled to present on Tuesday, May 20, 2008 at 11:20 am CEST. Interested parties may access

a live webcast of the presentation by visiting the CombinatoRx website at www.combinatorx.com.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a trial results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit www.combinatorx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its product candidates and their clinical potential, its plans for clinical and preclinical development of its product candidates, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, risks associated with the preclinical development of its product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(C) 2008 CombinatoRx, Incorporated. All rights reserved.

CombinatoRx, Incorporated
Robert Forrester, 617-301-7100
Fax: 617-301-7010
Executive Vice President, Chief Financial Officer
rforrester@combinatorx.com
or
CombinatoRx, Incorporated
Gina Nugent, 617-301-7099
VP, Corporate Communications and IR
Fax: 617-301-7010
gnugent@combinatorx.com